Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation.

Mahajan NP, Liu Y, Majumder S, Warren MR, Parker CE, Mohler JL, Earp HS, Whang YE.

Proc Natl Acad Sci U S A. 2007 May 15;104(20):8438-43. Epub 2007 May 9.

2.

Shepherding AKT and androgen receptor by Ack1 tyrosine kinase.

Mahajan K, Mahajan NP.

J Cell Physiol. 2010 Aug;224(2):327-33. doi: 10.1002/jcp.22162. Review.

3.

ACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers.

Mahajan K, Mahajan NP.

Oncogene. 2015 Aug 6;34(32):4162-7. doi: 10.1038/onc.2014.350. Epub 2014 Oct 27. Review.

4.

Androgen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinases.

Gelman IH.

Int J Biol Sci. 2014 Jun 5;10(6):620-6. doi: 10.7150/ijbs.8264. eCollection 2014. Review.

5.

Oncogenic activation of androgen receptor.

Kung HJ, Evans CP.

Urol Oncol. 2009 Jan-Feb;27(1):48-52. doi: 10.1016/j.urolonc.2008.06.002. Review.

6.

Androgen signal transduction and prostatic carcinoma.

Klocker H, Culig Z, Kaspar F, Hobisch A, Eberle J, Reissigl A, Bartsch G.

World J Urol. 1994;12(2):99-103. Review.

PMID:
8087144
7.

Androgen-receptor gene structure and function in prostate cancer.

Hakimi JM, Rondinelli RH, Schoenberg MP, Barrack ER.

World J Urol. 1996;14(5):329-37. Review.

PMID:
8912473
8.

Targeting tyrosine kinases and autophagy in prostate cancer.

Kung HJ.

Horm Cancer. 2011 Feb;2(1):38-46. doi: 10.1007/s12672-010-0053-3. Epub 2010 Dec 2. Review.

9.

Emerging biological observations in prostate cancer.

Shah S, Small E.

Expert Rev Anticancer Ther. 2010 Jan;10(1):89-101. doi: 10.1586/era.09.161. Review.

PMID:
20014889
10.

ACK1 tyrosine kinase: targeted inhibition to block cancer cell proliferation.

Mahajan K, Mahajan NP.

Cancer Lett. 2013 Sep 28;338(2):185-92. doi: 10.1016/j.canlet.2013.04.004. Epub 2013 Apr 15. Review.

11.

Posttranslational modification of the androgen receptor in prostate cancer.

van der Steen T, Tindall DJ, Huang H.

Int J Mol Sci. 2013 Jul 16;14(7):14833-59. doi: 10.3390/ijms140714833. Review.

12.

DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer.

D'Antonio JM, Vander Griend DJ, Isaacs JT.

Endocr Relat Cancer. 2009 Jun;16(2):325-32. doi: 10.1677/ERC-08-0205. Epub 2009 Feb 24. Review.

13.
14.

Maintaining and reprogramming genomic androgen receptor activity in prostate cancer.

Mills IG.

Nat Rev Cancer. 2014 Mar;14(3):187-98. doi: 10.1038/nrc3678. Review. Erratum in: Nat Rev Cancer. 2014 May;14(5). doi: 10.1038/nrc3722.

PMID:
24561445
15.

Androgen receptor phosphorylation: biological context and functional consequences.

Koryakina Y, Ta HQ, Gioeli D.

Endocr Relat Cancer. 2014 Aug;21(4):T131-45. doi: 10.1530/ERC-13-0472. Epub 2014 Jan 14. Review.

16.

Coupling transcription to RNA processing via the p68 DEAD box RNA helicase androgen receptor co-activator in prostate cancer.

Clark EL, Fuller-Pace FV, Elliott DJ, Robson CN.

Biochem Soc Trans. 2008 Jun;36(Pt 3):546-7. doi: 10.1042/BST0360546. Review.

PMID:
18482004
17.

Prostate cancer stem cells: the role of androgen and estrogen receptors.

Di Zazzo E, Galasso G, Giovannelli P, Di Donato M, Di Santi A, Cernera G, Rossi V, Abbondanza C, Moncharmont B, Sinisi AA, Castoria G, Migliaccio A.

Oncotarget. 2016 Jan 5;7(1):193-208. doi: 10.18632/oncotarget.6220. Review.

18.

Implications of Bcl-2 and its interplay with other molecules and signaling pathways in prostate cancer progression.

Kim JH, Lee H, Shin EA, Kim DH, Choi JB, Kim SH.

Expert Opin Ther Targets. 2017 Sep;21(9):911-920. doi: 10.1080/14728222.2017.1369044. Epub 2017 Aug 23. Review.

PMID:
28816549
19.

Androgen receptor-mediated non-genomic regulation of prostate cancer cell proliferation.

Liao RS, Ma S, Miao L, Li R, Yin Y, Raj GV.

Transl Androl Urol. 2013 Sep;2(3):187-96. doi: 10.3978/j.issn.2223-4683.2013.09.07. Review.

20.

Androgen receptors beyond prostate cancer: an old marker as a new target.

Munoz J, Wheler JJ, Kurzrock R.

Oncotarget. 2015 Jan 20;6(2):592-603. Review.

Supplemental Content

Support Center